title: Acral erythrodysesthesia syndrome caused by intravenous infusion of docetaxel in breast cancer.
abstract: Docetaxel-induced skin reactions include hypersensitivity, edema, skin toxicity with erythrodysesthesia syndrome, infusion site reactions, alopecia, nail onycholysis, nail pigmentation, photosensitivity, scleroderma, and others, for example, stomatitis and paresthesias. However, of all reported effects, the acral erythrodysesthesia syndrome has only rarely been described in the literature. We report on two female patients with breast cancer who on treatment with docetaxel developed acral erythrodysesthesia syndrome. It presented as bizarrely shaped, burning skin reactions at their hands and feet. Histology of skin biopsies revealed microscopic damages to the eccrine sweat glands in both patients. Skin patch testing with docetaxel was negative. None of the reports dealing with side effects of docetaxel chemotherapy has described acral erythrodysesthesia syndrome with the histologic features of syringo-squamous metaplasia and eccrine neutrophilic hidradenitis. We propose here that these characteristic histologic features are essential in the differentiation from fixed drug eruption and localized graft-versus-host disease.
authors.affiliation: Department of Dermatology, University of Cologne, University of Cologne, Germany.
authors.forename: Dorothee
authors.initials: D
authors.lastname: Eich
authors.forename: Karin
authors.initials: K
authors.lastname: Scharffetter-Kochanek
authors.forename: Hans Theodor
authors.initials: HT
authors.lastname: Eich
authors.forename: Iliana
authors.initials: I
authors.lastname: Tantcheva-Poor
authors.forename: Thomas
authors.initials: T
authors.lastname: Krieg
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy; D000077143:Docetaxel; D003875:Drug Eruptions / Q000209:etiology / Q000473:pathology; D004890:Erythema / Q000139:chemically induced / Q000473:pathology; D005260:Female; D005528:Foot; D006225:Hand; D006801:Humans; D007262:Infusions, Intravenous; D008875:Middle Aged; D017239:Paclitaxel / Q000009:adverse effects* / Q000031:analogs & derivatives*; D012871:Skin Diseases / Q000139:chemically induced* / Q000473:pathology; D013543:Sweat Gland Diseases / Q000139:chemically induced / Q000473:pathology; D013577:Syndrome; D043823:Taxoids
chemical_list: D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D017239:Paclitaxel